Detekce mutace JAK2 V617F u myeloproliferativních onemocnění - přehled a vlastní zkušenosti

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Detection of the JAK2 V617F mutation in myeloproliferative disorders - an overview and own experiences
Authors

KŘÍSTKOVÁ Z. DVOŘÁKOVÁ Dana RÁZGA Filip POSPÍŠILOVÁ Jana KUJÍČKOVÁ J. DOUBEK Michael MAYER Jiří

Year of publication 2009
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords JAK2 V617F; myeloproliferative disorders; real-time polymerase chain reaction; allelic discrimination; allele burden
Description The lack of reliable molecular markers is responsible for difficult detection and monitoring of PH-negative myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis. In recent years, the V617F point mutation in the JAK2 gene (JAK2V617F) come to be a feasible marker for confirmation and evaluation of such hematology disorders. In this paper we report a review of diagnostic methods developed for investigation of JAK2 gene mutations and we present our experience with detection of JAK2V617F. Two methods (allelic discrimination analysis and real-time polymerase chain reaction for quantitative determination of mutant allele burden) are compared and discussed. We conclude that this detection of JAK2V617F mutant allele burden may be used for establishing possible correlation between clinical symptoms and hematologic abnormalities for paients suffering from myeloproliferative disorders.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.